Skip to main content
Coral Laboratories Ltd. logo

Coral Laboratories Ltd. — Investor Relations & Filings

Ticker · 524506 ISIN · INE683E01017 LEI · 33580018OR2STOC8SS52 BSE.NS Manufacturing
Filings indexed 9 across all filing types
Latest filing 2026-05-30 Notice of Dividend Amou…
Country IN India
Listing BSE.NS 524506

About Coral Laboratories Ltd.

https://corallab.com/

Coral Laboratories Ltd. specializes in the development, manufacture, and marketing of a diverse range of pharmaceutical formulations. The product portfolio encompasses various dosage forms, including tablets, capsules, oral liquids, external preparations such as creams and ointments, and sterile injectables. These offerings address multiple therapeutic areas, including anti-bacterial, analgesic, anti-inflammatory, and gastrointestinal health. The company operates manufacturing facilities that adhere to WHO-GMP standards, ensuring rigorous quality management and compliance with global regulatory requirements. With a focus on providing accessible healthcare solutions, the organization serves a broad client base across domestic and international markets. Research and development efforts are centered on formulation optimization and the expansion of the product pipeline to meet evolving medical needs.

Recent filings

Filing Released Lang Actions
Final dividend of ? 2 per share
Notice of Dividend Amount Classification · 95% confidence The document is a letter to the stock exchange under SEBI LODR referencing Regulation 43 and notifying the Board’s recommendation of a final dividend (₹2.00 per share) for FY 2025-26. It announces the dividend amount (subject to AGM approval) rather than containing full financials or acting as a proxy, so it falls under Notice of Dividend Amount (DIV).
2026-05-30 English
Appointment of Cost Auditor
Regulatory Filings Classification · 87% confidence The document is a regulatory announcement under SEBI LODR to BSE notifying the appointment of the company’s Cost Auditor for the coming financial year. It does not contain actual financial statements or qualify as an audit report, nor is it a board/management change of directors. It is a compliance/regulatory filing notifying an event under Listing Regulations. Therefore it best fits the fallback category “Regulatory Filings” (RNS).
2026-05-30 English
Appointment of Internal Auditor
Board/Management Information Classification · 88% confidence The document is a stock exchange disclosure notifying BSE of the appointment of the company’s internal auditor by its Board of Directors, pursuant to SEBI Listing Regulations. This is an announcement of a change in management/governance personnel (internal auditor appointment), fitting squarely into the Board/Management Information category (MANG).
2026-05-30 English
The Board has approved ? 2 per share dividend.
Interim / Quarterly Report Classification · 85% confidence The document is a formal stock exchange filing under SEBI LODR Regulation 33 announcing the audited financial results for the quarter and year ended March 31, 2026. It includes full standalone financial statements (income statement, balance sheet, cash flows) and auditor opinions. It is not merely a press‐style earnings release (ER) nor a link‐only announcement (RPA). It is a comprehensive interim/quarterly financial report submitted to the exchange. Therefore, the correct classification is Interim / Quarterly Report (IR). FY 2026
2026-05-30 English
Results for the financial year ended on March 31, 2026
Earnings Release Classification · 85% confidence The document is a regulatory stock‐exchange filing (BSE Listing Obligations) disclosing the board‐approved audited financial results for the quarter and financial year ended March 31, 2026, complete with income statement, assets & liabilities, cash flow, and notes. It constitutes an earnings announcement of periodical financial results rather than a full annual report or standalone audit opinion. Therefore it best fits the “Earnings Release” category. FY 2026
2026-05-30 English
Outcome of Board meeting held on May 30, 2026
Interim / Quarterly Report Classification · 82% confidence The document is a formal stock‐exchange filing under SEBI LODR Regulation 33 titled “Outcome of Board meeting” held May 30, 2026, enclosing Audited Financial Results (Standalone) for the quarter and financial year ended March 31, 2026, complete with profit & loss numbers, assets & liabilities, cash flows, auditor’s report declaration, dividend recommendation, and auditor appointments. It is not a full annual report (10-K) with MD&A, nor just highlights (Earnings Release), but a comprehensive periodic financial report containing actual audited financial statements. Therefore it falls under Interim/Quarterly Report (IR). FY 2026
2026-05-30 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.